Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma
1 Mga view
• 07/18/23
0
0
I-embed
administrator
Mga subscriber
William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.
Magpakita ng higit pa
Mga Komento sa Facebook
SORT BY-
Mga Nangungunang Komento
-
Pinakabagong komento